Identification of Risk Factors for Bisphosphonate-Associated Atypical Femoral Fractures and Osteonecrosis of the Jaw in a Pharmacovigilance Database

被引:17
|
作者
Bejhed, Rebecca S. [1 ]
Kharazmi, Mohammad [2 ,3 ]
Hallberg, Par [4 ]
机构
[1] Uppsala Univ, Angstrom Lab, Uppsala, Sweden
[2] Uppsala Univ, Dept Surg Sci, Uppsala, Sweden
[3] Cent Hosp Vasteras, Vasteras, Sweden
[4] Uppsala Univ, Dept Med Sci, Uppsala, Sweden
关键词
bisphosphonates; osteonecrosis; atypical fracture; adverse drug reaction; drug safety; pharmacovigilance; risk factor; MEDICATION-RELATED OSTEONECROSIS; BONE; PREVENTION; ONJ;
D O I
10.1177/1060028016649368
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
BACKGROUND: Atypical femoral fractures (AFs) and osteonecrosis of the jaw (ONJ) are well-known adverse drug reactions (ADRs) associated with bisphosphonates. To prevent these ADRs and to aid in the search for pathogenic mechanisms, knowledge of risk factors can be helpful. Objective: To identify risk factors for bisphosphonate-related ONJ and AF. Methods: In this case-control study of reports of bisphosphonate-related ADRs from February 16, 1984, to October 16, 2013, in the Swedish national database of ADRs, we compared characteristics for cases of ONJ (n = 167) and AF (n = 55) with all other bisphosphonate-related ADRs (n = 565) with regard to demographic variables, clinical characteristics, and concomitant drug treatments. We adjusted for multiple comparisons with Bonferroni correction. Results: Time to onset of ADRs differed statistically significantly between cases of AF and controls (2156 vs 111 days). For ONJ versus controls, differences were statistically significant for time to onset (1240 vs 111 days), intravenous administration (40% vs 20%), dental procedures (49% vs 0.2%) and prostheses (5% vs 0%), cancer disease (44% vs 12%), multiple myeloma (21% vs 1%), rheumatoid arthritis (14% vs 5%), and treatment with antineoplastic agents and oxycodone. Conclusion: These results lend further evidence to previously identified risk factors for ONJthat is, intravenous bisphosphonate administration; invasive dental procedures and dental prostheses; cancer disease, in particular multiple myeloma; and possibly, long-term bisphosphonate treatment. A putative further risk factor is rheumatoid arthritis. Only long-term bisphosphonate treatment was more common among AF cases. The lack of overlap of risk factors between ONJ and AF suggests different pathogenic mechanisms.
引用
收藏
页码:616 / 624
页数:9
相关论文
共 50 条
  • [41] Teriparatide’s role in the management of bisphosphonate-associated osteonecrosis of the jaw
    G. Subramanian
    S. Y. P. Quek
    Osteoporosis International, 2012, 23 : 2727 - 2728
  • [42] Is bisphosphonate-associated osteonecrosis of the jaw caused by soft tissue toxicity?
    Reid, Ian R.
    Bolland, Mark J.
    Grey, Andrew B.
    BONE, 2007, 41 (03) : 318 - 320
  • [43] Lack of response to teriparatide therapy for bisphosphonate-associated osteonecrosis of the jaw
    J. Narváez
    J. A. Narváez
    C. Gómez-Vaquero
    J. M. Nolla
    Osteoporosis International, 2013, 24 : 731 - 733
  • [44] Nonexposed Variant of Bisphosphonate-associated Osteonecrosis of the Jaw: A Case Series
    Fedele, Stefano
    Porter, Stephen R.
    D'Aiuto, Francesco
    Aljohani, Suad
    Vescovi, Paolo
    Manfredi, Maddalena
    Arduino, Paolo G.
    Broccoletti, Roberto
    Musciotto, Anna
    Di Fede, Olga
    Lazarovici, Tony S.
    Campisi, Giuseppina
    Yarom, Naom
    AMERICAN JOURNAL OF MEDICINE, 2010, 123 (11): : 1060 - 1064
  • [45] Tetraparesis after surgical treatment of bisphosphonate-associated osteonecrosis of the jaw
    Zaami, Simona
    Busardo, Francesco P.
    Amatruda, Alfonso
    Ricci, Giovanna
    Esposito, Vincenzo
    JOURNAL OF NEUROSURGICAL SCIENCES, 2018, 62 (01) : 97 - 99
  • [46] CONCOMITANT ATYPICAL FEMORAL FRACTURE AND OSTEONECROSIS OF THE JAW IN BISPHOSPHONATE USERS
    Correa-Perez, A.
    Sanchez-Castellanos, C.
    Cruz-Jentoft, A. J.
    OSTEOPOROSIS INTERNATIONAL, 2017, 28 : S328 - S328
  • [47] Resource utilization in cancer patients with bisphosphonate-associated osteonecrosis of the jaw
    Najm, M. S.
    Solomon, D. H.
    Woo, S-B
    Treister, N. S.
    ORAL DISEASES, 2014, 20 (01) : 94 - 99
  • [48] Teriparatide's role in the management of bisphosphonate-associated osteonecrosis of the jaw
    Subramanian, G.
    Quek, S. Y. P.
    OSTEOPOROSIS INTERNATIONAL, 2012, 23 (11) : 2727 - 2728
  • [49] Teriparatide Accelerates Healing of Bisphosphonate-Associated Atypical Femoral Fractures in Patients with Osteoporosis.
    Miyakoshi, Naohisa
    Aizawa, Toshiaki
    Sasaki, Satoshi
    Ando, Shigeru
    Maekawa, Shigeto
    Aonuma, Hiroshi
    Tsuchie, Hiroyuki
    Sasaki, Hiroshi
    Kasukawa, Yuji
    Shimada, Yoichi
    JOURNAL OF BONE AND MINERAL RESEARCH, 2014, 29 : S115 - S115
  • [50] Prevalence and Risk Factors of Bisphosphonate-Associated Osteonecrosis of the Jaw in Prostate Cancer Patients with Advanced Disease Treated with Zoledronate
    Walter, Christian
    Al-Nawas, Bilal
    Groetz, Knut A.
    Thomas, Christian
    Thueroff, Joachim W.
    Zinser, Viktoria
    Gamm, Heinold
    Beck, Joachim
    Wagner, Wilfried
    EUROPEAN UROLOGY, 2008, 54 (05) : 1066 - 1072